News Release

Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp

June 11, 2021
  • Mr. Patterson brings nearly 30 years of senior leadership experience in biotechnology, including leading Audentes Therapeutics from inception through acquisition over an eight-year period
  • Kush M. Parmar, M.D., Ph.D., Managing Partner at 5AM Ventures, to continue as a member of the Vor Board of Directors
  • Tania Philipp promoted to Vor’s Chief People Officer from Vice President and Head of People

CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies to be used in combination with targeted therapies for the treatment of cancer, today announced Matthew R. Patterson as Chairman of its Board of Directors.

Mr. Patterson, who joined Vor’s Board as a member in October 2020, brings nearly 30 years of senior leadership experience in the research, development and commercialization of innovative therapeutics, most recently at Audentes Therapeutics, Inc., which he co-founded and led as the company’s Chief Executive Officer from its inception in 2012 through its acquisition by Astellas Pharma Inc. in January 2020.

Prior to leading Audentes, he was an Entrepreneur-In-Residence with OrbiMed and held multiple senior-level positions at Amicus Therapeutics, Inc., including President and Chief Operating Officer as well as acting Chief Executive Officer. Before Amicus he held multiple positions of increasing responsibility at Genzyme Corporation and BioMarin Pharmaceutical Inc. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy sector. Mr. Patterson served as ARM’s Chairman in 2019 and 2020.

Mr. Patterson succeeds Kush M. Parmar, M.D., Ph.D., Managing Partner at 5AM Ventures, who will continue his service to Vor as a member of the Board of Directors.

“Matt’s experience as a company builder is unparalleled, having turned an idea on paper into one of the leading biotechnology companies in our industry. His strategic counsel on matters related to the clinical development and manufacturing of novel therapies has already proven invaluable to our team as we prepare for the next stages of our growth,” said Robert Ang, M.B.B.S., M.B.A., Vor’s President and Chief Executive Officer. “We are further thrilled that Kush will continue his service to Vor as a member of our Board of Directors and thank him for his successful leadership through the critical, early stages of our journey.”

“I am honored to lead Vor’s Board during this exceptional time of growth for the company as it moves ever closer to transforming the lives of cancer patients through its innovative therapies,” said Matthew R. Patterson, Vor’s Chairman. “I am inspired by the boldness, ingenuity and elegance of Vor’s scientific platform and look forward to continuing to advise the Vor team as they make the necessary steps to turn the innovative potential of these treatments into a reality for patients.”

In addition to Mr. Patterson’s appointment, Vor also today announced the promotion of Tania Philipp to Vor’s Chief People Officer from the company’s Vice President and Head of People.

In her new role, Ms. Philipp will continue to hire, retain, and support an industry-leading team with expertise across multiple disciplines, including scientific research, clinical development and the manufacturing of novel therapies. Ms. Philipp brings more than 15 years of experience helping life science companies grow and progress, having previously served as the Vice President and Head of Human Resources at Tango Therapeutics. She has also held various senior human resources positions at a number of companies, including Bavarian Nordic, Mendel Biotechnology, Sunesis Pharmaceuticals, Pearl Therapeutics (acquired by AstraZeneca) and Protein Design Labs.

About Vor Biopharma
Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancer cells while sparing healthy cells. For more information please visit

Forward-Looking Statements
This press release contains forward-looking statements within the meaning the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent annual or quarterly report and in other reports the Company has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Investor Contact:
Chris Brinzey
Westwicke, an ICR Company
+1 339-970-2843

Media Contact:
Rebecca Spalding
Ten Bridge Communications
+1 646-509-3831